Table 3. Discontinuation of hydroxyurea use and prevalence of adverse drug reactions (ADRs) based on patient demographics and duration of use.
| Demographics | Discontinuation | ADR present | ||||
|---|---|---|---|---|---|---|
| Yes n (%) |
No n (%) |
p-value | Yes n (%) |
No n (%) |
p-value | |
| Gender | 1.000 | 0.066 | ||||
| Male | 36 (56.3) | 28 (43.8) | 11 (17.2) | 53 (82.8) | ||
| Female | 37 (57.8) | 27 (42.2) | 21 (32.8) | 43 (67.2) | ||
| Age, years | 0.142 | 0.076 | ||||
| < 18 | 14 (42.4) | 19 (57.6) | 4 (12.1) | 29 (87.9) | ||
| 18–30 | 40 (61.5) | 25 (38.5) | 17 (26.2) | 48 (73.8) | ||
| 31–45 | 19 (63.3) | 11 (36.7) | 11 (36.7) | 19 (63.3) | ||
| 46–60 | - | - | - | - | ||
| Duration of use, months | 0.002 | 0.015 | ||||
| 0–2 | 13 (86.7) | 2 (13.3) | 9 (60.0) | 6 (40.0) | ||
| > 2–≤ 6 | 9 (64.3) | 5 (35.7) | 4 (28.6) | 10 (71.4) | ||
| > 6– ≤ 12 | 9 (90.0) | 1 (10.0) | 3 (30.0) | 7 (70.0) | ||
| > 12–≤ 36 | 20 (55.6) | 16 (44.4) | 4 (11.1) | 32 (88.9) | ||
| > 36–≤ 60 | 8 (57.1) | 6 (42.9) | 4 (28.6) | 10 (71.4) | ||
| > 60 | 11 (32.4) | 24 (68.6) | 6 (17.1) | 29 (82.9) | ||